Claudin18.2 defines a prognostically distinct subgroup of intrahepatic cholangiocarcinoma via CD8+ T-cell exclusion
CLDN18.2 is a tumor-specific prognostic biomarker in ICC, marking aggressive subsets with early recurrence. Combined CLDN18.2/CD8<sup>+</sup> TILs stratification enhances prognostic precision and suggests synergistic potential for CLDN18.2 targeted therapies with immunomodulation. These findings warrant clinical validation to guide personalized treatment strategies.
Authors
- Yi Pan (ORCID: https://orcid.org/0000-0001-9734-6398)
- Zhenyun Guo
- Fuli Li (ORCID: https://orcid.org/0000-0003-0381-2234)
- Baobing Yin (ORCID: https://orcid.org/0000-0001-7651-5295)
- Da Xu
- Chengui Yu
- Ying Zhu
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Wuxi People's Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fonc.2025.1636367
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05